Lanean...
Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment
AIMS: Renal disease is a frequent comorbidity of type 2 diabetes mellitus (T2DM) and an important factor complicating the choice of glucose-lowering drugs. The aim of this analysis was to evaluate the efficacy and safety of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin (5 mg/day) in mono, d...
Gorde:
| Argitaratua izan da: | Diabetes Obes Metab |
|---|---|
| Egile Nagusiak: | , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Blackwell Publishing Ltd
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4288982/ https://ncbi.nlm.nih.gov/pubmed/24612167 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12281 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|